A paradigm shift for evaluating pharmacotherapy for Alzheimer's disease: The 10-patient screening protocol

Consultant Pharmacist

Volumn 28, Issue 7, 2013, Pages 443-454

  Weinstein, James D ^a   Gonzalez, Edgar R ^b,c   Egleton, Richard D ^c   Hunt, David A ^d  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Cabell Huntington Hospital   (United States)

^c MARSHALL UNIVERSITY   (United States)

^d The College of New Jersey   (United States)

Author keywords

Alzheimer's disease; Dementia; Microglial dysfunction; Neuroinflammation; Neurophysiology; Pharmacotherapy; Polypharmacy; Reactive oxygen species; Research; Screening; Tau phosphorylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E4; IMMUNOGLOBULIN; PLACEBO; REACTIVE OXYGEN METABOLITE; TAU PROTEIN;

ALLELE; ALZHEIMER DISEASE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFLAMMATION; MEDICATION COMPLIANCE; MONOTHERAPY; NERVOUS SYSTEM INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PEER REVIEW; POLYPHARMACY; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SENILE PLAQUE; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 84880024507     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2013.443     Document Type: Review

References (60)

1. Hyman BT. Amyloid dependent and amyloid-independent stages of Alzheimer's disease. Arch Neuro 2011;68:1062-4
2. Swerdlow RH, Kahn SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypothesis 2004;63:8-20. (Pubitemid 38887104)
3. Massaad CA, Pautler RG, Klann E. Mitochondrial superoxide: a key player in Alzheimer's disease. Aging 2009;9:758-61.
4. Wen Y, Li W, Poteet EC. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem 2011;286:16504-15.
5. Nunomura A, Castellani RJ, Zhu X et al. Involvement of oxidative stress in Alzheimer's disease. J Neuropathol Exp Neurol 2006;65:631-41. (Pubitemid 44297254)
6. Schulz JB, Lindenau J, Syfrid J et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000;267:4904-11. (Pubitemid 30641286)
7. Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicol 2011;283:65-87.
8. Durany N, Munch G, Michel T et al. Investigations on oxidative stress and therapeutical implications in dementia. Eur Arch Psychiatr Clin Neurosci 1999;249 Suppl 3:68-73.
9. Fuller S, Steele M, Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease - do they neglect their neurosupportive roles? Mutat Res 2010;690:40-9.
10. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Nat Acad Sci 1996;93:11213-8.
11. Kramer P, Cirrito J, Wesson D et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012;235:1503-6.
12. Wishik CM, Edwards PC, Lai RY et al. Selective inhibition of Alzheimer's disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci 1995;93:11213-8. (Pubitemid 26333144)
13. Balin BJ, Little CS, Hammond CJ. Chlamydophila pneumoniae and the etiology of late onset Alzheimer's disease. J Alzheimer Dis 2008;13:317-80.
14. Priller C, Bauer T, Mitteregger G et al. Synapse formation and function is modulated by the amyloid precursor protein. J Neurosci 2006;26:7212-21.
15. Matsui T, Ingelsson M, Fukumoto H et al. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res 2007;1161:116-23. (Pubitemid 47068429)
16. Goate A, Chartier-Harlin MC, Mullan M et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-6. (Pubitemid 21912142)
17. Murrell J, Farlow M, Ghetti B et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991;254:97-9. (Pubitemid 21917324)
18. Chartier-Harlin MC, Crawford F, Houlden H et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991;353:844-6. (Pubitemid 21912637)
19. Citron M, Oltersdorf T, Haass C et al. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature 1992;360:672-4. (Pubitemid 23007680)
20. Guela C, Wu C-K, Saroff D et al. Aging renders the brain vulnerable to amyloid B-protein neurotoxicity. Nat Med 1998;4:827-31. (Pubitemid 28331025)
21. Coma M, Guix F, Ill-Raga G et al. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol Aging 2008;29:969-80. (Pubitemid 351697981)
22. Cai Z, Zhao D, Ratka A. Oxidative stress and beta-amyloid protein in Alzheimer's disease. Neuromol Med 2011;13:223-50.
23. Gunther EC, Strittmater SM. D-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med 2010;88:331-8.
24. Floden AM, Li S, Combs CK. Beta-amyloid stimulated microglia induced neuron death via synergistic stimulation of tumor necrosis factor A and NMDA receptors. J Neuro Sci 2005;25:2566-75. (Pubitemid 40365168)
25. Manczak M, Anedonda T, Henson E et al. Mitochondria are a direct site of AB accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molec Genet 2006;15:9:1447-9.
26. Devi L, Pradahu BM, Galati DF et al. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 2006;26:9057-68. (Pubitemid 44319397)
27. Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer's disease. J Neurochem 2006;96:1-13.
28. Alive G, Palacious HH, Gasimov E. Oxidative stress induced mitochondrial failure and vascular hypoperfusion as a key initiator for the development of Alzheimer's disease. Pharmaceuticals 2010;3:158-87.
29. De la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs 2012;72:49-66.
30. Facecchia K, Fochesato L, Ray SD et al. Oxidative toxicity in neurodegenerative disease; role of mitochondrial dysfunction and therapeutic strategies. J Toxicol 2011(doi:10.1155/2011/683728).
31. Higgins GC, Beart PM, Shin YS et al. Oxidative stress: emerging mitochondrial and cellular themes and variations in neuronal injury. J Alzheimers Dis 2010;20 Suppl 2:S453-73.
32. Ding Q, Dimayuga E, Keller JN. Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. Curr Alzheimer Res Feb 2007;4:73-9.
33. Rahmadi A, Steiner N, Munch G. Advanced glycation endproducts as gerontoxins and biomarkers for carbonyl based degenerative processes in Alzheimer's disease. Clin Chem Lab Med 2011;49:385-91.
34. Munch G, Duether-Conrad W, Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease - a target for neuroprotective treatment strategies? J Neuro Transm Suppl 2002;62:303-7. (Pubitemid 37046674)
35. Lopes KO, Sparks DL, Streit WJ. Microglial dystrophy in the aged Alzheimer's disease brain is associated with ferritin aminoreactivity. Glia 2008;56:1048-60.
36. Yoon J, An S, Kyeong I et al. Oxidative modification of ferritin induced by hydrogen peroxide. Biochem Mol Bio Reports 2011;44: 165-9.
37. Fuller S, Steele M, Munch G. Activated astroglia during chronic inflammation in Alzheimer's disease - do they neglect their neurosupportive roles? Mutat Res 2010;690:40-9.
38. Streit WJ, Braak H, Xue Q et al. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009;118:475-85.
39. Winblad B, Floravanti M, Dolezal T et al. Therapeutic use of nicergoline. Clin Drug Invest 2008;28:9:533-52.
40. Owen L, Sunram-Lea SI. Metabolic agents that enhance ATP can improve cognitive functioning: a review of the evidence for glucose oxygen pyruvate, creatine, and l-carnitine. Nutrients 2011;3:735-55.
41. Kumar R, Atamna H. Therapeutic approaches to delay the onset of Alzheimer's disease. J Aging Res 2011;1:1-12. (doi:10.406.1/2011/820903).
42. He G, Luo W, Li P et al. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease. Nature 2010;467:dei:10/1038/ nature09325.
43. Vingtdeux V, Dreses-Werringloer U, Zhau H et al. Therapeutic potential of resveratrol in Alzheimer's disease. BNC Neuro Sci 2008;9: S2-S6.
44. Holmquist L, Stuchbury G, Barbum K et al. Lipoic acid as a novel treatment for Alzheimer's disease and related dementias. Pharmacol Ther 2007;113:154-64. (Pubitemid 44969927)
45. Liu G, Men P, Perry G et al. Nanopartical and iron chelators as a potential novel Alzheimer's therapy. Methods Mol Biol 2010;610:123-44.
46. Stefanovic SD, Schinzel R, Reiderer P et al. AGEs in brain aging: AGE inhibitors as neuroprotective and antidementia drugs. Biogerentology 2001;2:19-34.
47. Griffin WS. Inflammation and neurodegenerative diseases. Am J Clin Nutr 2006;83:470S-4S. (Pubitemid 44713221)
48. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimer Dement 2009;5:388-97.
49. Saver JL, Kalafut M. Combination therapies and the theoretical limits of evidence-based medicine. Neuroepidemiol 2001;10:57-64. (Pubitemid 32453722)
50. Xie SX, Ewbank DC, Chittams J et al. Rate of decline in Alzheimer's disease measured by dementia severity rating scale. Alzheimers Dis Assoc Disord 2009;23:268-74.
51. Berg L. Clinical dementia rating (CDR). Psychopharmacol Bull 1988;25:639.
52. Galasko D, Bennet D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer's Dis Assoc Disord 1997;11 Suppl 2:S33-S9.
53. Clark CM, Ewbank DC. Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer's disease. Alzheimers Dis Assoc Disord 1996;10:31-9. (Pubitemid 26073890)
54. Iopen CG, Olin JT, Schmeider LS. Can caregivers independently rate cognitive and behavioral symptoms in Alzheimer's disease patients? A longitudinal analysis. Am J Geriatr Psychiatry 1999;7:321-30. (Pubitemid 29468660)
55. Jorn AF. The value of informant reports for the assessment and prediction of dementia. J Am Geriatr Soc 2003;51:881-2.
56. Gelb DJ. Measurement of progression in Alzheimer's disease: a clinician's perspective. Stat Med 2000;19:1393-400. (Pubitemid 30346232)
57. Foster NL, Chase TN, Mansi L. Cortical abnormalities in Alzheimer's disease. Ann Neurol 1984;16:649-51.
58. Newberg A, Cotter A, Udeshi M et al. A metabolic imaging severity rating scale for the assessment of cognitive impairment. Clin Nuclear Med 2003;28:565-70. (Pubitemid 38281921)
59. Lopez OL, Becker JT, Sweet RA et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2003;15:346-53. (Pubitemid 36999378)
60. Livingston G, Johnston K, Katona C et al. Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005;162:1996-2021. (Pubitemid 41598254)